Research analysts at Evercore ISI started coverage on shares of Agilent Technologies (NYSE:A) in a report released on Wednesday, The Fly reports. The brokerage set an “outperform” rating on the medical research company’s stock.
A has been the topic of several other reports. Morgan Stanley restated an “overweight” rating on shares of Agilent Technologies in a research note on Tuesday, November 14th. Zacks Investment Research lowered Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, November 16th. Robert W. Baird reaffirmed a “buy” rating and issued a $72.00 target price on shares of Agilent Technologies in a research report on Friday, November 24th. ValuEngine lowered Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, Barclays increased their target price on Agilent Technologies from $67.00 to $71.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 21st. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Agilent Technologies currently has an average rating of “Buy” and a consensus price target of $68.34.
Shares of Agilent Technologies (NYSE A) traded up $1.72 on Wednesday, reaching $69.32. The company had a trading volume of 1,698,899 shares, compared to its average volume of 1,373,349. Agilent Technologies has a 52-week low of $46.35 and a 52-week high of $70.93. The company has a market capitalization of $22,310.00, a PE ratio of 33.17, a PEG ratio of 2.03 and a beta of 1.28. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.30 and a quick ratio of 2.85.
Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Monday, November 20th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.05. Agilent Technologies had a return on equity of 16.95% and a net margin of 15.30%. The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the business posted $0.59 earnings per share. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. sell-side analysts predict that Agilent Technologies will post 2.58 EPS for the current year.
In other news, CFO Didier Hirsch sold 12,964 shares of the firm’s stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $69.00, for a total transaction of $894,516.00. Following the transaction, the chief financial officer now directly owns 184,851 shares of the company’s stock, valued at $12,754,719. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael R. Mcmullen sold 22,481 shares of the firm’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $68.77, for a total value of $1,546,018.37. Following the transaction, the chief executive officer now directly owns 336,637 shares in the company, valued at $23,150,526.49. The disclosure for this sale can be found here. Insiders sold 132,588 shares of company stock worth $9,186,710 over the last ninety days.
A number of hedge funds have recently made changes to their positions in A. Dupont Capital Management Corp bought a new position in Agilent Technologies during the third quarter valued at about $101,000. Balentine LLC boosted its stake in Agilent Technologies by 2.9% during the second quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock valued at $106,000 after buying an additional 50 shares in the last quarter. Sun Life Financial INC boosted its position in shares of Agilent Technologies by 26,144.4% in the 2nd quarter. Sun Life Financial INC now owns 2,362 shares of the medical research company’s stock valued at $140,000 after purchasing an additional 2,353 shares during the period. Acrospire Investment Management LLC boosted its position in shares of Agilent Technologies by 92.3% in the 2nd quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock valued at $148,000 after purchasing an additional 1,200 shares during the period. Finally, Fiduciary Trust Co. acquired a new position in shares of Agilent Technologies in the 2nd quarter valued at $186,000.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.